Lv53
1162 积分 2024-01-16 加入
Cost-effectiveness of Sacituzumab Govitecan versus Single-agent Chemotherapy for Patients with Metastatic Triple-Negative Breast Cancer in China
9天前
已关闭
Triple negative breast cancer: what clinical progress have we seen in the last 5 years?
21天前
已完结
Advances in systemic therapies for triple negative breast cancer
21天前
已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
22天前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
22天前
已完结
Triple-Negative Breast Cancer
23天前
已完结
Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment
1个月前
已关闭
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
2个月前
已完结
Unmet Needs in Maintenance Therapy for Extensive Stage Small Cell Lung Cancer
2个月前
已完结
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study
2个月前
已完结
皖公网安备34019202002308
